Le coin des experts
Si vous êtes intéressés par une publication en particulier, contactez-vous via le formulaire de contact. Vous revevrez en prime un audio de 30 minutes par Dr Christophe Hugnet, vétérinaire expert en génétique et pharmacologie.
Acepromazine
Deshpande, D., Hill, K.E., Mealey, K.L., Chambers, J.P. and Gieseg, M.A., 2016. The effect of the canine ABCB1-1Δ mutation on sedation after intravenous administration of acepromazine. Journal of Veterinary Internal Medicine, 30(2), pp.636-641.
Afoxalaner
Drag, M., Tielemans, E. and Mitchell, E., 2022. Safety of oral afoxolaner formulated with or without milbemycin oxime in homozygous MDR1-deficient collie dogs. Journal of Veterinary Pharmacology and Therapeutics, 45(4), pp.373-379
Apomorphine
Campbell, O., de Lorimier, L.P. and Mealey, K.L., 2017. Adverse reaction to apomorphine in a collie homozygous for the ABCB1-1Δ mutation. Journal of Small Animal Practice, 58(2), pp.119.
Butorphanol
Mealey, K.L., 2006. Adverse Drug Reactions in Herding Breeds. Compendium of Continuing Education for the Practicing Veterinarian, 28, pp.23-33.
Cyclosporine A
Mackin, A.J., Riggs, C., Beatty, T., Mealey, K., Boothe, D. and Archer, T., 2020. Excessive cyclosporine-associated immunosuppression in a dog heterozygous for the MDR1 (ABCB1-1Δ) mutation. Journal of the American Animal Hospital Association, 56(3), pp.190-195.
Dexamethasone
Mealey, K.L., Gay, J.M., Martin, L.G. and Waiting, D.K., Comparison of the hypothalamic-pituitary-adrenal axis in MDR1-1D and MDR1 wildtype dogs.
Digoxin
Henick, R.A., Kellum, H.B., Bentjen, S.A. and Mealey, K.L., 2006. Digoxin and mexiletine sensitivity in a collie with the mdr1 mutation. Journal of Veterinary Internal Medicine, 20, pp.415-417.
Doramectin
Yas-Natan, E., Shamir, S. and Kleinbart, S., 2003. Doramectin toxicity in a collie. Veterinary Record, 153, pp.718-720.
Doxorubicin
Mealey, K.L., 2013. Adverse drug reactions associated with drug transporters. Veterinary Clinics of North America: Small Animal Practice, 43(5), pp.1067-1078.
Doxorubicin
Gustafson, D.L. and Thamm, D.H., 2010. Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transporters. Journal of Veterinary Internal Medicine, 24(3), pp.579-586.
Eprinomectin
Mealey, K.L., Burke, N.S., Villarino, N.F., Court, M.H. and Heusser, J.P., 2024. Application of eprinomectin-containing parasiticides at label doses causes neurological toxicosis in cats homozygous for ABCB11930_1931del TC. Journal of Veterinary Pharmacology and Therapeutics, 47(3), pp.226-230.
Emodepside
Gaens, D., Leithauser, C., Hamann, M. and Geyer, J., 2019. Adverse drug reactions after administration of empdepside/praziquantel (Profender) in an MDR1 mutant Australian shepherd dog: case report. Frontiers in Veterinary Science, 6, p.296.
Fluralaner
Walther, F.M., Paul, A.J., Allan, M.J., Roepke, R.K. and Nuernberger, M.C., 2014. Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration. Parasites & Vectors, 7, p.86.
Grapiprant
Heit, M.C., Mealey, K.L. and King, S.B., 2021. Tolerance and pharmacokinetics of Galliprant TM administered orally to collies homozygous for MDR1-1Δ. Journal of Veterinary Pharmacology and Therapeutics, 44(5), pp.705-713.
Ivermectin
Mealey, K.L., Bentjen, S.A., Gay, J. and Cantor, G.H., 2001. Ivermectin sensitivity in Collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics, 11, pp.727-733.
Ivermectin
Mealey, K.L. and Burke, N.S., 2015. Identification of a nonsense mutation in feline ABCB1. Journal of Veterinary Pharmacology and Therapeutics, 38(5), pp.429-433.
Loperamide
Mealey, K.L., Greene, S., Bagley, R., Gay, J., Tucker, R., Gavin, P., Waiting, D., Schmidt, K. and Nelson, F., 2008. P-glycoprotein contributes to the blood-brain, but not blood-CSF, barrier in a spontaneous canine P-glycoprotein knockout model. Drug Metabolism and Disposition, 36(6), pp.1073-1079.
Hugnet, C., Cadore, J.L., Buronfosse, F., Pineau, X., Mathet, T. and Berny, P.J., 1996. Loperamide poisoning in the dog. Veterinary and Human Toxicology, 38(1), pp.31-33.
Maropitant
Mealey, K.L., Dassanayake, S. and Burke, N.S., 2017. Establishment of a cell line for assessing drugs as canine P-glycoprotein substrates: Proof of principle. Journal of Veterinary Pharmacology and Therapeutics, 40(5), pp.545-551.
Milbemycin
Barbet, J., Snook, T., Gay, J.M. and Mealey, K.L., 2009. ABCB1 (MDR1) genotype is associated with adverse reactions in dogs treated with milbemycin oxime for generalized demodicosis. Veterinary Dermatology, 20, pp.111-114.
Moxidectin
Janko, C. and Geyer, J., 2013. Moxidectin has a lower neurotoxic potential but comparable brain penetration in P-glycoprotein-deficient CF-1 mice compared to ivermectin. Journal of Veterinary Pharmacology and Therapeutics, 36(3), pp.275-284.
Selamectin
Griffin, J., Fletcher, N., Clemence, R., Blanchflower, S. and Brayden, D.J., 2005. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. Journal of Veterinary Pharmacology and Therapeutics, 28(3), pp.257-265.
Vinblastine
Mealey, K.L. and Fidel, J., 2015. P-glycoprotein-mediated drug interactions in oncology patients. Journal of Veterinary Internal Medicine, 29(1), pp.1-6.
Vincristine
Mealey, K.L., Fidel, J., Gay, J.M., Impellizeri, J., Clifford, C. and Bergman, P.J., 2008. ABCB1-1Δ Polymorphism can predict hematologic toxicity in dogs treated with vincristine. Journal of Veterinary Internal Medicine, pp.996-1000.
Commandez votre kit MDR1
Votre compagnon est-il hypersensible à certains médicaments? Découvrez le status de votre animal grâce à notre test génétique simple et fiable afin de prendre soin de lui en toute tranquilité